These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 15004434

  • 1. Role of Angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling.
    Korshunov VA, Massett MP, Carey RM, Berk BC.
    J Vasc Res; 2004; 41(2):148-56. PubMed ID: 15004434
    [Abstract] [Full Text] [Related]

  • 2. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
    Pu Q, Larouche I, Schiffrin EL.
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
    [Abstract] [Full Text] [Related]

  • 3. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
    Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE.
    Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654
    [Abstract] [Full Text] [Related]

  • 4. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
    Pu Q, Touyz RM, Schiffrin EL.
    J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
    [Abstract] [Full Text] [Related]

  • 5. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
    Azizi M, Lamarre-Cliche M, Labatide-Alanore A, Bissery A, Guyene TT, Ménard J.
    J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
    Raasch W, Dominiak P, Dendorfer A.
    J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
    [Abstract] [Full Text] [Related]

  • 7. The cardiovascular actions of omapatrilat in spontaneously hypertensive rats.
    Dong Y, Zhou H, Shaffer E, Atamas N, Liao WC, Wei C.
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S1-5. PubMed ID: 11716799
    [Abstract] [Full Text] [Related]

  • 8. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
    Bäcklund T, Palojoki E, Grönholm T, Eriksson A, Vuolteenaho O, Laine M, Tikkanen I.
    Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
    [Abstract] [Full Text] [Related]

  • 9. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T, Cheruvu M, Olsufka R, Sandvik ER, Lane CE, Budman J, Hill CM, Klein U, Hegde SS.
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [Abstract] [Full Text] [Related]

  • 10. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats.
    Pu Q, Schiffrin EL.
    Am J Hypertens; 2001 Oct; 14(10):1067-72. PubMed ID: 11710787
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
    Massien C, Azizi M, Guyene TT, Vesterqvist O, Mangold B, Ménard J.
    Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
    [Abstract] [Full Text] [Related]

  • 12. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
    Mifsud SA, Burrell LM, Kubota E, Jaworski K, Cooper ME, Wilkinson-Berka JL.
    Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
    [Abstract] [Full Text] [Related]

  • 13. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
    Jandeleit-Dahm K, Lassila M, Davis BJ, Candido R, Johnston CI, Allen TJ, Burrell LM, Cooper ME.
    J Hypertens; 2005 Nov; 23(11):2071-82. PubMed ID: 16208151
    [Abstract] [Full Text] [Related]

  • 14. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC.
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [Abstract] [Full Text] [Related]

  • 15. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats.
    Intengan HD, Schiffrin EL.
    Hypertension; 2000 Jun; 35(6):1221-5. PubMed ID: 10856267
    [Abstract] [Full Text] [Related]

  • 16. In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.
    Azizi M, Massien C, Michaud A, Corvol P.
    Hypertension; 2000 Jun; 35(6):1226-31. PubMed ID: 10856268
    [Abstract] [Full Text] [Related]

  • 17. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
    Kubota E, Dean RG, Hubner RA, Casley DJ, Johnston CI, Burrell LM.
    Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
    [Abstract] [Full Text] [Related]

  • 18. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
    Kostova E, Jovanoska E, Zafirov D, Jakovski K, Maleska V, Slaninka-Miceska M.
    Bratisl Lek Listy; 2005 Sep; 106(12):407-11. PubMed ID: 16642666
    [Abstract] [Full Text] [Related]

  • 19. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
    Pu Q, Amiri F, Gannon P, Schiffrin EL.
    J Hypertens; 2005 Feb; 23(2):401-9. PubMed ID: 15662229
    [Abstract] [Full Text] [Related]

  • 20. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C, Fortin D, Rouleau JL, Molinaro G, Adam A.
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.